Management of the cardinal features of andropause

American Journal of Therapeutics

Volumn 13, Issue 2, 2006, Pages 145-160

  Mooradian, Arshag D ^a,c   Korenman, Stanley G ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Aging; Erectile failure; Sexuality; Testosterone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANDRIOL TESTOCAP; ANDRO LA; ANDROGEN; ANDROID; ANDROIL; ANDROPOSITORY; ANDROSTANOLONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DELATEST; DEP ANDRO; FLUOXYMESTERONE; METANDREN LINGUETS; METHYLTESTOSTERONE; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROSTAVASIN; PSEUDOEPHEDRINE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL; TESTEX LEO; TESTONE LA; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; TESTOSTERONE UNDECANOATE; TESTOVIT; TESTRIN PA; TRAZODONE; VARDENAFIL; VIROHORMONE; YOHIMBINE;

AGING; ANDROGEN METABOLISM; ANDROPAUSE; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG HALF LIFE; ERECTILE DYSFUNCTION; HUMAN; HYPOGONADISM; HYPOTENSION; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MEMORY; MENOPAUSE; MENTAL CONCENTRATION; MOOD; PRIAPISM; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUALITY; TESTOSTERONE BLOOD LEVEL; AGE; AGED; GROWTH, DEVELOPMENT AND AGING; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMPOTENCE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; TESTIS;

AGE FACTORS; AGED; AGING; ANDROGENS; ANDROPAUSE; HUMANS; HYPOGONADISM; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMPOTENCE; MALE; MIDDLE AGED; RISK FACTORS; SEXUAL BEHAVIOR; TESTIS;

EID: 33646580029     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000132252.80403.c9     Document Type: Article

References (171)

1. Korenman SG, Mooradian AD, Hendrick V. Changes in men as they age: the manopause. In: Lobo RA, Kelsey J, Marcus R, eds. Menopause. Biology and Pathobiology. San Diego: Academic Press; 2002:111-133.
2. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol (A) Biol Sci Med Sci. 2002;57:M76-M99.
3. Mooradian AD. Biology of aging. In: Felsenthal SJG, Steinberg FU, eds. Rehabilitation of the Aging and the Elderly Patient. Baltimore: Williams & Wilkins; 1994:3-10.
4. Mooradian AD, Greiff V. Sexuality in older women. Arch Intern Med. 1990;150:1033-1038.
5. Kaufman JM, Vermeulen A. Declining gonadal function in elderly men. Baillieres Clin Endocrinol Metab. 1997;11:289-309.
6. Nowak FV, Mooradian AD. Endocrine function and dysfunction. In: Birren JE, ed. Encyclopedia of Gerontology, Vol. 1. San Diego: Academic Press; 1996:477-491.
7. Mooradian AD. Mechanisms of age-related endocrine alterations. Part I. Drugs Aging. 1993;3:81-97.
8. Mooradian AD. Mechanisms of age-related endocrine alterations. Part II. Drugs Aging. 1993;3:131-146.
9. Mooradian AD. Geriatric sexuality and chronic diseases. Clin Geriatr Med. 1991;7:113-131.
10. Morley JE, Kaiser FE, Perry HMIII, et al. Longitudinal changes in testosterone, luteinizing hormone and follicle-stimulating hormone in healthy older men. Metabolism. 1996;46:410-413.
11. Morley JE, Kaiser FE, Raum WJ, et al. Potentially predictive and manipulatable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci U S A. 1997;94:7537-7542.
12. Gray A, Nunez AA, Siegel LI, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016-1025.
13. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589-598.
14. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effect of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
15. Deslypere J, Kaufman JM, Vermeulen T, et al. Influence of age on pulsatile luteinizing hormone release and responsiveness of gonadotrophs to sex hormone feedback in men. J Clin Endocrinol Metab. 1987;64:68-73.
16. Tenover JS, Matsumoto AM, Clifton DK, et al. Age-related alterations in the circadian rhythms of pulsatile luteinizing hormone and testosterone secretion in healthy men. J Gerontol. 1988;43:M163-M169.
17. Touitou Y, Fe'vre M, Lagoguey M, et al. Age-and mental health-related circadian rhythms of plasma levels of melatonin, prolactin, luteinizing hormone and follicle-stimulating hormone in man. J Endocrinol. 1981;91:467-475.
18. Kaiser F, Viosca SP, Morley JE, et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc. 1988;36:511-519.
19. Korenman S, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab. 1990;71:963-969.
20. Vermeulen A, Kaufman JM. Aging of the hypothalamopituitary testicular axis in men. Horm Res. 1995;43:25-28.
21. Tenover JS, McLachlan RI, Dahl KD, et al. Decreased serum inhibin levels in normal elderly men: evidence for a decline in Sertoli cell function with aging. J Clin Endocrinol Metab. 1988;67:455-459.
22. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56:1278-1281.
23. Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxford). 2003;58:710-717.
24. Touitou Y, Lagoguey M, Bogdan A, et al. Seasonal rhythms of plasma gonadotrophins: their persistence in elderly men and women. J Endocrinol. 1983;96:15-21.
25. Winters SJ, Sherins RJ, Troen P. The gonadotropinsuppressive activity of androgen is increased in elderly men. Metabolism. 1986;33:1052-1059.
26. Winters JJ, Troen P. Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men. Evidence for co-existent primary testicular insufficiency and an impairment in gonadotropin secretion. J Clin Endocrinol Metab. 1982;55:560-565.
27. Muta K, Kato KI, Akamine Y, et al. Age-related changes in the feedback regulation of gonadotropin secretion by sex steroids in men. Acta Endocrinol. 1981;96:154-162.
28. Tenover JS, Matsumoto AM, Plymate SR, et al. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion response to clomiphene citrate. J Clin Endocrinol Metab. 1987;65:118-126.
29. Harman SM, Tsitouras PD, Costa PT, et al. Reproductive hormones in aging men. II. Basal pituitary gonadotropins and gonadotropin responses to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 1982;54:547-551.
30. Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab. 1980;51:35-40.
31. Watson RR, Huls A, Araghinikuam M, et al. Dehydroepiandrosterone and diseases of aging. Drugs Aging. 1996;9:274-291.
32. Dhatariya KK, Nair KS. Dehydroepiandrosterone: Is there a role for replacement? Mayo Clin Proc. 2003;78:1257-1273.
33. Barrett-Connor E, Khaw KT, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315:1519-1524.
34. Feldman HA, Johannes CB, Araujo AB, et al. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2001;153:79-89.
35. Ishimura T, Pages L, Horton R. Altered metabolism of androgens in elderly men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1977;45:695-701.
36. Moore RJ, Wilson JD. The effect of androgenic hormones on the reduced nicotinamide dinucleotide phosphate 4-3ketosteroid 5-alpha-oxidoreductase of rat ventral prostate. J Clin Endocrinol Metab. 1973;95:581-592.
37. Tunn S, Hochstrate H, Grunwald I, et al. Effect of aging on kinetic parameters of 5a-reductase in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab. 1988;67:979-985.
38. Baker HW, Burger HG, de Krester DM, et al. Changes in the pituitary-testicular system with age. Clin. Endocrinol. 1976;5:349-372.
39. Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab. 1979;48:338-340.
40. Djavan B, Remzi M, Erne B, et al. The pathophysiology of benign prostatic hyperplasia. Drugs Today. 2002;38:867-876.
41. Tunn S, Haumann R, Hey J, et al. Effect of aging on kinetic parameters of 3a (b)-hydroxysteroid oxidoreductases in epithelium and stroma of human normal and hyperplastic prostate. J Clin Endocrinol Metab. 1990;71:732-739.
42. Hardy DO, Scher HI, Bogenreider T, et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab. 1996;81:4400-4405.
43. Zitzmann M, Depenbusch M, Gromoll J, et al. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal American Journal of Therapeutics (2005) 12(2) Mooradian and Korenman pharmacogenetic study. J Clin Endocrinol Metab. 2003;88:2049-2054.
44. Rosner W, Hrub DJ, Khan MS, et al. Sex hormone binding globulin mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Mol Biol. 1999;69:481-485.
45. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev. 1987;8:1-28.
46. Banerjee PP, Banerjee S, Lai JM, et al. Age-dependent and lobe-specific spontaneous hyperplasia in the brown Norway rat prostate. Biol Reprod. 1998;59:1163-1170.
47. Tsitouras P, Martin CE, Harman SM. Relationship of serum testosterone to sexual activity in healthy elderly men. J Gerontol. 1982;37:288-293.
48. Davidson J, Camargo C, Smith E. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab. 1979;48:955-958.
49. Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983;57:557-562.
50. Bancroft J, Wu FCW Changes in erectile responsiveness during androgen therapy. Arch Sex Behav. 1983;12:59-66.
51. Bagatell C, Heiman J, Rivier J, et al. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab. 1994;78:711-716.
52. Leipheimer R, Sachs B. Relative androgen-sensitivity of the vascular and striated-muscle systems regulating penile erection in rats. Physiol Behav. 1993;54:1085-1090.
53. Park KH, Kim SW, Kim KD, et al. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int. 1999;83:327-333.
54. Chamness SL, Ricker DD, Crone JK, et al. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril. 1995;63:1101-1107.
55. Heaton J, Varrin S. Effects of castration and exogenous testosterone supplementation in an animal model of penile erection. J Urol. 1994;151:797-800.
56. Baba K, Yajima M, Carrier S, et al. Delayed testosterone replacement restores nitric oxide synthase-containing nerve fibers and the erectile response in rat penis. BJU Int. 2000;85:953-958.
57. Lugg J, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology. 1995;136:1495-1501.
58. Schiavi R, White D, Mandeli J, et al. Hormones and nocturnal penile tumescence in healthy aging men. Arch Sex Behav. 1992;22:207-215.
59. O'Carroll R, Bancroft J. Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. Br J Psychiatry. 1984;145:146-151.
60. Schiavi RC, White D, Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med. 1991;53:363-374.
61. Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA. 1983;249:1736-1740.
62. Davis SS, Viosca SP, Guralnik M, et al. Evaluation of impotence in older men. West J Med. 1985;142:499-505.
63. Sciavi RC, Mandeli J, Schreiner-Engel P. Sexual satisfaction in healthy aging men. J Sex Marital Ther. 1994;20:3-13.
64. Yesavage JA, Davidson J, Widlow L, et al. Plasma testosterone levels, depression, sexuality, and age. Biol Psychol. 1985;20:222-225.
65. Davies R, Harris B, Thomas DR, et al. Salivary testosterone levels and major depressive illness in men. Br J Psychiatry. 1992;161:629-632.
66. Levitt AJ, Joffe RT. Total and free testosterone in depressed men. Acta Psychiatr Scand. 1988;77:346-348.
67. Nilsson P, Moller L, Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. J Intern Med. 1995;237:479-486.
68. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab. 1996;81:3578-3583.
69. Christ-Crain M, Muller B, Gasser T, et al. No clinical relevance of biochemical hypoandrogenism in elderly men. Presented at the Endocrine Society Annual Program, 2003;424.
70. Schow D, Redmon B, Pryor JL. Male menopause: how to define it, how to treat it. Postgrad Med. 1997;101:62-79.
71. McKinlay J. Is there an epidemiologic basis for a male climacteric syndrome? The Massachusetts Male Aging Study. In: Hammond CB, Hoseltire FP, eds. Menopause: Evaluation, Treatment, and Health Concerns. New York, NY: Alan R. Liss;1989:163-192.
72. Gatz M, Hurwicz ML. Are old people more depressed? Cross-sectional data on Center for Epidemiological Studies Depression Scale Factors. Psychol Aging. 1990;5:284-290.
73. Penninx B, Guralnik JM, Ferrucci L, et al. Depressive symptoms and physical decline in community-dwelling older persons. JAMA. 1998;279:1720-1726.
74. Beekman A, Deeg DJ, van Tilburg T, et al. Major and minor depression in later life: a study of prevalence and risk factors. J Affect Disord. 1995;36:65-75.
75. Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. JAMA. 1997;277:1618-1623.
76. Hirschfeld R, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the under treatment of depression. JAMA. 1997;277:333-340.
77. Gilbody S, Whitty P, Grimshaw J, et al. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA. 2003;289:3145-3151.
78. Zisook S. Depression in late life. Diagnosis, course, and consequences. Postgrad Med. 1996;100:143-148.
79. Murrell S, Himmelfarb S, Wright K. Prevalence of depression and its correlates in older adults. Am J Epidemiol 1983;117:173-185.
80. Turner RJ, Noh S. Physical disability and depression: a longitudinal analysis. J Health Soc Behav. 1988;29:23-37.
81. Araujo A, Durante R, Feldman HA, et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998;60:458-465.
82. Thase M, Reynolds CF, Jennings JR, et al. Nocturnal penile tumescence is diminished in depressed men. Biol Psychiatry. 1988;24:33-46.
83. Feldman H, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151:54-61.
84. Rybash J, Roodin PA, Hoyer WJ, eds. Adult Development and Aging, 3rd ed. Madison, WI: Brown & Benchmark. 1995, 276-290.
85. National Institutes of Health Consensus Development Panel on Impotence. JAMA. 1993;270:83-90.
86. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537-544.
87. Korenman SG. New insights into erectile dysfunction: a practical approach. Am J Med. 1998;105:135-144.
88. Krane R, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med. 1989;321:1648-1659.
89. Korenman SG. Advances in the understanding and management of erectile dysfunction. J Clin Endocrinol Metab. 1995;80:1985-1988.
90. Korenman SG. Sexual function and dysfunction. In: Wilson J, Foster DW, eds. Williams Textbook of Endocrinology. Philadelphia: WB Saunders; 1998:927-938.
91. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813.
92. Persson C, Diederichs W, Lue TF, et al. Correlation of altered penile ultrastructure with clinical arterial evaluation. J Urol. 1989;142:1462-1468.
93. Akkus E, Carrier S, Baba K, et al. Structural alterations in the tunica albuginea of the penis: impact of Peyronie's disease, ageing and impotence. Br J Urol. 1997;79:47-53.
94. Mooradian AD, Viosca SP, Kaiser FE, et al. Penile Raynaud's phenomenon: a possible cause of erectile failure. Am J Med. 1988;85:748-750.
95. Metz ME, Nesvacil LJ, Abuzzahab F, et al. Premature ejaculation: a psychophysiological review. J Sex Marital Ther. 1997;23:3-23.
96. Waldinger MD, Hengeveld MW, Zwinderman AH. Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. Br J Urol. 1997;79:592-595.
97. Haensel SM, Klem TM, Hop WC, et al. Fluoxetine and premature ejaculation: a double-blind, crossover, placebo-controlled study. J Clin Psychopharmacol. 1998;18:72-77.
98. Balbay MD, Yildiz M, Salvarci A, et al. Treatment of premature ejaculation with sertraline. Int Urol Nephrol. 1998;30:81-83.
99. Lee HS, Song DH, Kim CH, et al. An open clinical trial of fluoxetine in the treatment of premature ejaculation. J Clin Psychopharmacol. 1996;16:379-382.
100. Haensel SM, Rowland DL, Kallan KD. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol. 1996;156:1310-1315.
101. Smith KW, Feldman HA, McKinley JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in aging men. Clin Endocrinol 2000;53:703-711.
102. Heineman AJ, Zimmerman J, Vermeulen A, et al. A new aging male's symptoms (AMS) rating scale. Aging Male. 1999;2:105-114.
103. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239-1242.
104. Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab. 1997;82:2014-2015.
105. Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone assay; are the results in men clinically useful? Clin Chem. 1998;44:2178-2182.
106. Vermeulin A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
107. Morley JE, Patrick P, Perry HM3rd. Evaluation of assays available to measure free testosterone. Metabolism. 2002;51:554-559.
108. Korenman S. Advances in the understanding and management of erectile dysfunction. J Clin Endocrinol Metab. 1995;80:1985-1988.
109. Urban RJ, Bodenbury YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995;269:E820-E826.
110. Sih R, Morley JE, Kaiser FE, et al. Testosterone replace ment in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661-1667.
111. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092-1098.
112. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670-2677.
113. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testos terone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88:2673-2681.
114. Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol. 2003;58A:1002-1008.
115. Bhasin S, Bagatell CJ, Bremner WJ, et al. Issues in testosterone replacement in older men. J Clin Endocrinol Metab. 1998;83:3435-3448.
116. Bagatell CJ, Bremner WJ. Androgens in men: uses and abuses. N Engl J Med. 1996;334:707-714.
117. Rhoden EL, Morgentaler A. Risks of testosterone replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-492.
118. Korenman SG, Viosca S, Garza D, et al. Androgen therapy of hypogonadal men with transscrotal testosterone systems. Am J Med. 1987;83:471-478.
119. Yu Z, Gupta SK, Hwang SS, et al. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. J Clin Pharmacol. 1997;37:1139-1145.
120. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with biweekly injections of testosterone enanthate for the treatment of hypo-gonadal men. J Clin Endocrinol Metab. 1999;84:3469-3478.
121. Wilson DE, Meikle AW, Boike SC, et al. Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men. J Clin Pharmacol. 1998;38:54-59.
122. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites. A general clinical research center study. J Clin Endocrinol Metab. 2000;85:964-969.
123. Swerdloff RS, Wang C, Cunningham G, et al. Long term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85:4500-4510.
124. Marbury T, Hamill E, Bachand R, et al. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to Androgel. Biopharm Drug Dispos. 2003;24:115-120.
125. de Lignieres B. Transdermal dihydrotestosterone treatment of "andropause". Ann Med. 1993;25:235-241.
126. Kunelius P, Lukkarinen O, Hannuksela ML, et al. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002;87:1467-1472.
127. Salehian B, Wang C, Alexander G, et al. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate - a clinical research center study. J Clin Endocrinol Metab. 1995;80:3567-3575.
128. Dobs AS, Hoover DR, Chen MC, et al. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J Clin Endocrinol Metab. 1998;83:33-39.
129. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab. 1997;82:3793-3796.
130. Kenny AM, Prestwood KM, Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocr Res. 2000;26:153-168.
131. Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997;49:191-196.
132. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxford). 1994;341-349.
133. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118-1126.
134. Mohr BA, Feldman HA, Kalish LA, et al. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology. 57:930-935.
135. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-224.
136. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319-326.
137. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822-830.
138. Morley JE, Korenman SG, Kaiser FE, et al. Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older males. Am J Med. 1988;84:445-448.
139. Nurnberg HG, Hensley PL, Gelenberg AJ, et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289:56-64.
140. Kloner RA, Brown M, Prisant LM, et al. Effect of sildenafil in patients with erectile dysfunction taking anti-hypertensive therapy. Sildenafil Study Group. Am J Hypertens. 2001;14:70-73.
141. Aranda P, Ruilope LM, Calvo C, et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish National Study. Am J Hypertens. 2004;17:139-145.
142. Ralph D, McNicholas T. UK management guidelines for erectile dysfunction. BMJ. 2000;321:499-503.
143. Kaplan H. Psychogenic impotence. Curr Ther Endocrinol Metab. 1994;5:323-328.
144. Buffum J. Pharmacosexology: the effects of drugs on sexual function - a review. J Psychoactive Drugs. 1982;14:5-44.
145. Wein A, Van Arsdale K. Drug-induced male sexual dysfunction. Urol Clin North Am. 1988;15:23-31.
146. Lue T, Hricak H, Schmidt RA, et al. Functional evaluation of penile veins by cavernosography in papaverine-induced erection. J Urol. 1986;135:479-482.
147. Kaufman J, Borges FD, Fitch WP, et al. Evaluation of erectile dysfunction by dynamic infusion cavernosometry and cavernosography (DICC). Multi-institutional study. Urology. 1993;41:445-451.
148. Ackerman M, Dattilio JP, Antoni MH, et al. The predictive significance of patient-reported sexual functioning in Rigiscan sleep evaluations. J Urol. 1991;146:1559-1563.
149. Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs. 1999;57:967-989.
150. Goldstein I, Lue TF, Padma NH, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397-1404.
151. Hellstrom WJG, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double blind, placebo-controlled trial. J Androl. 2002;23:763-771.
152. Ormrod D, Easthope SE, Figgitt D. Vardenafil. Drugs Aging. 2002;19:217-227.
153. Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients. A Rigiscan and pharmacokinetic study. World J Urol. 2001;19:32-39.
154. Padma-Nathan H, McMurray JG, Pullman WE, et al. IC351 On-Demand Dosing Study Group. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 2001;13:2-9.
155. Milligan PA, Marshall SF, Karlsson MO. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol. 2002;53:455-525.
156. Patterson BE, Bedding AW, Jewell H, et al. Dose-normalized pharmacokinetics of tadalafil administered as a single dose to healthy volunteers [abstract]. Eur Urol. 2002;1(Suppl):152.
157. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur J Med Res. 2002;7:435-446.
158. Turko IV, Ballard SA, Francis SH, et al. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol. 1999;56:124-130.
159. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation. 1999;99:168-177.
160. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol. 2000;86:175-181.
161. Meinhardt W, Schmitz PI, Kropman RF, et al. Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impot Res. 1997;9:163-165.
162. Kunelius PD, Hakkinen J, Lukkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology. 1997;49:441-444.
163. Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol. 1998;159:122-124.
164. Dula E, Keating W, Siami PF, et al. and the Apomorphine Study Group. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. Urology. 2000;56:130-135.
165. Korenman SG, Viosca SP. Treatment of vasculogenic sexual dysfunction with pentoxifylline. J Am Geriatr Soc. 1993;41:363-366.
166. Padma-Nathan H, Stecher VJ, Sweeney M, et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology. 2003;62:400-403.
167. Korenman S, Viosca SP, Kaiser FE, et al. Use of a vacuum tumescence device in the management of impotence. J Am Geriatr Soc. 1990;38:217-220.
168. Linet O, Neff L. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Invest. 1994;72:139-149.
169. Linet OI, Ogring FG, The Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in Mooradian and Korenman men with erectile dysfunction. N Engl J Med. 1996;334:873-878.
170. Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology. 2000;55:109-113.
171. Petrou S, Barrett D. The use of penile prostheses in erectile dysfunction. Semin Urol. 1990;8:138-152.